RecruitingPhase 1NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies
Studying NON RARE IN EUROPE: Adenocarcinoma of stomach
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nurix Therapeutics, Inc.
- Principal Investigator
- Linda Neuman, MDNurix Therapeutics, Inc.
- Intervention
- NX-1607(drug)
- Enrollment
- 345 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (17)
- City of Hope, Duarte, California, United States
- University of Southern California, Los Angeles, California, United States
- University of California, San Francisco, San Francisco, California, United States
- University of Colorado School of Medicine, Aurora, Colorado, United States
- University of Chicago, Chicago, Illinois, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- University of Oklahoma, Oklahoma City, Oklahoma, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- University of Virginia, Charlottesville, Virginia, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom
- Addenbrookes Cambridge University Hospital, Cambridge, United Kingdom
- Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
- Sarah Cannon Research Institute, London, United Kingdom
- The Christie NHS Foundation Trust, Manchester, United Kingdom
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05107674 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Adenocarcinoma of stomach
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07431281Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2AstraZeneca
- ACTIVE NOT RECRUITINGNCT07448493Local Treatment Strategies for Brain Metastases of Gastric and Esophageal CancerBlokhin's Russian Cancer Research Center
- RECRUITINGPHASE1, PHASE2NCT07262619EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsEikon Therapeutics
- RECRUITINGPHASE2NCT07070466Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEAMassachusetts General Hospital
- RECRUITINGPHASE2NCT07102901Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaJiangsu HengRui Medicine Co., Ltd.
- RECRUITINGPHASE2NCT07212933The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled TrialChinese PLA General Hospital
- RECRUITINGNCT07032961A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies ScreeningNanfang Hospital, Southern Medical University
- RECRUITINGPHASE1, PHASE2NCT06710756Lead-212 PSV359 Therapy for Patients With Solid TumorsPerspective Therapeutics
See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach →